SPECIALTY GUIDELINE MANAGEMENT

JEVTANA (cabazitaxel) cabazitaxel

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Jevtana is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

Compendial Uses

- 1. Subsequent treatment for castration-resistant distant metastatic disease previously treated with a docetaxel-based regimen or in patients who are not candidates for, or are intolerant of docetaxel
- 2. Subsequent treatment for castration-resistant distant metastatic disease previously treated with novel hormone therapy (e.g., enzalutamide [Xtandi] or abiraterone [Zytiga])

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

Metastatic castration-resistant prostate cancer (CRPC)

Authorization of 6 months may be granted for the treatment of metastatic castration-resistant prostate cancer when previously treated with any of the following:

- A. A docetaxel-containing regimen or in patients who are not candidates for or who are intolerant to docetaxel
- B. Novel hormone therapy (e.g., enzalutamide [Xtandi], abiraterone [Zytiga])

III. CONTINUATION OF THERAPY

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

IV. REFERENCES

- 1. Jevtana [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; July 2023.
- 2. Cabazitaxel [package insert]. Princeton, NJ: Sandoz Inc.; January 2023.
- 3. The NCCN Drugs & Biologics Compendium® © 2023 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed August 1, 2023.

cabazitaxel-Jevtana 1932-A SGM P2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number(s)

1932-A

cabazitaxel-Jevtana 1932-A SGM P2023.docx

© 2023 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

